Download PDF
Semin Neurol 2012; 32(03): 246-254
DOI: 10.1055/s-0032-1329202
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Myotonic Dystrophy: From Bench to Bedside

Nicholas E. Johnson
1   Department of Neurology, University of Rochester, Rochester, New York
,
Chad R. Heatwole
1   Department of Neurology, University of Rochester, Rochester, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
01 November 2012 (online)

    Permissions and Reprints

Abstract

Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are autosomal dominant disorders classically characterized by muscle weakness, myotonia, and early-onset cataracts. Patients may also experience dysfunction of the heart, brain, gastrointestinal, endocrine, skin, and respiratory systems. The pathogenesis of myotonic dystrophy is related to trinucleotide (DM1) and tetranucleotide (DM2) repeat expansions that produce toxic mutant mRNA with subsequent interference of RNA-splicing mechanisms. Optimal disease management includes symptomatic care, screens for asymptomatic disease, counseling, and a multidisciplinary approach. The authors review the pathogenesis, clinical features, diagnostic tests, and standard management of DM1 and DM2 and outline promising clinical research for patients with these disorders.

Keywords

myotonic dystrophy type 1 - myotonic dystrophy type 2 - congenital myotonic dystrophy
 

  • References

  • 1 Harper PS. Myotonic Dystrophy. London: W.B. Saunders; 2001
    Google Scholar
  • 2 Day JW, Ricker K, Jacobsen JF , et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003; 60 (4) 657-664
    CrossrefPubMedGoogle Scholar
  • 3 López de Munain A, Blanco A, Emparanza JI , et al. Prevalence of myotonic dystrophy in Guipúzcoa (Basque Country, Spain). Neurology 1993; 43 (8) 1573-1576
    CrossrefPubMedGoogle Scholar
  • 4 Mathieu J, De Braekeleer M, Prévost C. Genealogical reconstruction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean area (Quebec, Canada). Neurology 1990; 40 (5) 839-842
    CrossrefPubMedGoogle Scholar
  • 5 Medica I, Marković D, Peterlin B. Genetic epidemiology of myotonic dystrophy in Istria, Croatia. Acta Neurol Scand 1997; 95 (3) 164-166
    PubMedGoogle Scholar
  • 6 Suominen T, Bachinski LL, Auvinen S , et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 2011; 19 (7) 776-782
    CrossrefPubMedGoogle Scholar
  • 7 Brook JD, McCurrach ME, Harley HG , et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992; 68 (4) 799-808
    CrossrefPubMedGoogle Scholar
  • 8 Fu YH, Pizzuti A, Fenwick Jr RG , et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992; 255 (5049) 1256-1258
    CrossrefPubMedGoogle Scholar
  • 9 Mahadevan M, Tsilfidis C, Sabourin L , et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 1992; 255 (5049) 1253-1255
    CrossrefPubMedGoogle Scholar
  • 10 De Temmerman N, Sermon K, Seneca S , et al. Intergenerational instability of the expanded CTG repeat in the DMPK gene: studies in human gametes and preimplantation embryos. Am J Hum Genet 2004; 75 (2) 325-329
    CrossrefPubMedGoogle Scholar
  • 11 Heatwole CR, Bode R, Johnson NE , et al. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 2012; 79 (4) 348-357
    CrossrefPubMedGoogle Scholar
  • 12 Nakamori M, Gourdon G, Thornton CA. Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. Mol Ther 2011; 19 (12) 2222-2227
    CrossrefPubMedGoogle Scholar
  • 13 Gourdon G, Radvanyi F, Lia AS , et al. Moderate intergenerational and somatic instability of a 55-CTG repeat in transgenic mice. Nat Genet 1997; 15 (2) 190-192
    CrossrefPubMedGoogle Scholar
  • 14 Joseph JT, Richards CS, Anthony DC, Upton M, Perez-Atayde AR, Greenstein P. Congenital myotonic dystrophy pathology and somatic mosaicism. Neurology 1997; 49 (5) 1457-1460
    CrossrefPubMedGoogle Scholar
  • 15 Mankodi A, Takahashi MP, Jiang H , et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002; 10 (1) 35-44
    CrossrefPubMedGoogle Scholar
  • 16 Mankodi A, Teng-Umnuay P, Krym M, Henderson D, Swanson M, Thornton CA. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol 2003; 54 (6) 760-768
    CrossrefPubMedGoogle Scholar
  • 17 Wheeler TM. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics 2008; 5 (4) 592-600
    CrossrefPubMedGoogle Scholar
  • 18 Osborne RJ, Lin X, Welle S , et al. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet 2009; 18 (8) 1471-1481
    CrossrefPubMedGoogle Scholar
  • 19 Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002; 10 (1) 45-53
    CrossrefPubMedGoogle Scholar
  • 20 Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29 (1) 40-47
    CrossrefPubMedGoogle Scholar
  • 21 Savkur RS, Philips AV, Cooper TA , et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet 2004; 74 (6) 1309-1313
    CrossrefPubMedGoogle Scholar
  • 22 Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, Cooper TA. Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A 2008; 105 (7) 2646-2651
    CrossrefPubMedGoogle Scholar
  • 23 Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, Cooper TA. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 2009; 119 (12) 3797-3806
    CrossrefPubMedGoogle Scholar
  • 24 Bachinski LL, Udd B, Meola G , et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet 2003; 73 (4) 835-848
    CrossrefPubMedGoogle Scholar
  • 25 Liquori CL, Ricker K, Moseley ML , et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293 (5531) 864-867
    CrossrefPubMedGoogle Scholar
  • 26 Ranum LP, Rasmussen PF, Benzow KA, Koob MD, Day JW. Genetic mapping of a second myotonic dystrophy locus. Nat Genet 1998; 19 (2) 196-198
    CrossrefPubMedGoogle Scholar
  • 27 Cardani R, Mancinelli E, Giagnacovo M, Sansone V, Meola G. Ribonuclear inclusions as biomarker of myotonic dystrophy type 2, even in improperly frozen or defrozen skeletal muscle biopsies. Eur J Histochem 2009; 53 (2) 107-111
    PubMedGoogle Scholar
  • 28 Lam SL, Wu F, Yang H, Chi LM. The origin of genetic instability in CCTG repeats. Nucleic Acids Res 2011; 39 (14) 6260-6268
    CrossrefPubMedGoogle Scholar
  • 29 Timchenko LT, Tapscott SJ, Cooper TA, Monckton DG. Myotonic dystrophy: discussion of molecular basis. Adv Exp Med Biol 2002; 516: 27-45
    PubMedGoogle Scholar
  • 30 Ranum LP, Day JW. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2. Curr Neurol Neurosci Rep 2002; 2 (5) 465-470
    CrossrefPubMedGoogle Scholar
  • 31 Huichalaf C, Schoser B, Schneider-Gold C, Jin B, Sarkar P, Timchenko L. Reduction of the rate of protein translation in patients with myotonic dystrophy 2. J Neurosci 2009; 29 (28) 9042-9049
    CrossrefPubMedGoogle Scholar
  • 32 Salisbury E, Schoser B, Schneider-Gold C , et al. Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients. Am J Pathol 2009; 175 (2) 748-762
    CrossrefPubMedGoogle Scholar
  • 33 Logigian EL, Blood CL, Dilek N , et al. Quantitative analysis of the “warm-up” phenomenon in myotonic dystrophy type 1. Muscle Nerve 2005; 32 (1) 35-42
    CrossrefPubMedGoogle Scholar
  • 34 Groh WJ, Groh MR, Saha C , et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008; 358 (25) 2688-2697
    CrossrefPubMedGoogle Scholar
  • 35 Fung KC, Corbett A, Kritharides L. Myocardial tissue velocity reduction is correlated with clinical neurologic severity in myotonic dystrophy. Am J Cardiol 2003; 92 (2) 177-181
    CrossrefPubMedGoogle Scholar
  • 36 Sabovic M, Medica I, Logar N, Mandić E, Zidar J, Peterlin B. Relation of CTG expansion and clinical variables to electrocardiogram conduction abnormalities and sudden death in patients with myotonic dystrophy. Neuromuscul Disord 2003; 13 (10) 822-826
    CrossrefPubMedGoogle Scholar
  • 37 Vinereanu D, Bajaj BP, Fenton-May J, Rogers MT, Mädler CF, Fraser AG. Subclinical cardiac involvement in myotonic dystrophy manifesting as decreased myocardial Doppler velocities. Neuromuscul Disord 2004; 14 (3) 188-194
    CrossrefPubMedGoogle Scholar
  • 38 Arsenault ME, Prévost C, Lescault A, Laberge C, Puymirat J, Mathieu J. Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions. Neurology 2006; 66 (8) 1248-1250
    CrossrefPubMedGoogle Scholar
  • 39 Ciafaloni E, Mignot E, Sansone V , et al. The hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology 2008; 70 (3) 226-230
    CrossrefPubMedGoogle Scholar
  • 40 Gibbs III JW, Ciafaloni E, Radtke RA. Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy. Sleep 2002; 25 (6) 662-665
    PubMedGoogle Scholar
  • 41 Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 2007; 36 (3) 294-306
    CrossrefPubMedGoogle Scholar
  • 42 Meola G, Sansone V, Perani D , et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord 2003; 13 (10) 813-821
    CrossrefPubMedGoogle Scholar
  • 43 Sistiaga A, Urreta I, Jodar M , et al. Cognitive/personality pattern and triplet expansion size in adult myotonic dystrophy type 1 (DM1): CTG repeats, cognition and personality in DM1. Psychol Med 2010; 40 (3) 487-495
    CrossrefPubMedGoogle Scholar
  • 44 Gaul C, Schmidt T, Windisch G , et al. Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology 2006; 67 (2) 350-352
    CrossrefPubMedGoogle Scholar
  • 45 Weber YG, Roebling R, Kassubek J , et al. Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology 2010; 74 (14) 1108-1117
    CrossrefPubMedGoogle Scholar
  • 46 Modoni A, Silvestri G, Vita MG, Quaranta D, Tonali PA, Marra C. Cognitive impairment in myotonic dystrophy type 1 (DM1): a longitudinal follow-up study. J Neurol 2008; 255 (11) 1737-1742
    CrossrefPubMedGoogle Scholar
  • 47 Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C. Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 2004; 61 (12) 1943-1947
    CrossrefPubMedGoogle Scholar
  • 48 Wozniak JR, Mueller BA, Ward EE, Lim KO, Day JW. White matter abnormalities and neurocognitive correlates in children and adolescents with myotonic dystrophy type 1: a diffusion tensor imaging study. Neuromuscul Disord 2011; 21 (2) 89-96
    CrossrefPubMedGoogle Scholar
  • 49 Rönnblom A, Andersson S, Danielsson A. Mechanisms of diarrhoea in myotonic dystrophy. Eur J Gastroenterol Hepatol 1998; 10 (7) 607-610
    CrossrefPubMedGoogle Scholar
  • 50 Moxley III RT, Meola G. The myotonic dystrophies. In: Rosenberg RN, DiMauro S, Paulson HL, Ptacek L, Nestler EJ, , eds. The Molecular and Genetic Basis of Neurologic and Psychiatric Disease. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 511-518
    Google Scholar
  • 51 Heatwole CR, Miller J, Martens B, Moxley III RT. Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. Arch Neurol 2006; 63 (8) 1149-1153
    CrossrefPubMedGoogle Scholar
  • 52 Zaki M, Boyd PA, Impey L, Roberts A, Chamberlain P. Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome. Ultrasound Obstet Gynecol 2007; 29 (3) 284-288
    CrossrefPubMedGoogle Scholar
  • 53 Campbell C, Sherlock R, Jacob P, Blayney M. Congenital myotonic dystrophy: assisted ventilation duration and outcome. Pediatrics 2004; 113 (4) 811-816
    CrossrefPubMedGoogle Scholar
  • 54 Moxley III RT, Meola G, Udd B, Ricker K. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October, 2000, Loosdrecht, The Netherlands. Neuromuscul Disord 2002; 12 (3) 306-317
    CrossrefPubMedGoogle Scholar
  • 55 Ricker K, Koch MC, Lehmann-Horn F , et al. Proximal myotonic myopathy. Clinical features of a multisystem disorder similar to myotonic dystrophy. Arch Neurol 1995; 52 (1) 25-31
    CrossrefPubMedGoogle Scholar
  • 56 Day JW, Roelofs R, Leroy B, Pech I, Benzow K, Ranum LP. Clinical and genetic characteristics of a five-generation family with a novel form of myotonic dystrophy (DM2). Neuromuscul Disord 1999; 9 (1) 19-27
    CrossrefPubMedGoogle Scholar
  • 57 Thornton CA, Johnson K, Moxley III RT. Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes. Ann Neurol 1994; 35 (1) 104-107
    CrossrefPubMedGoogle Scholar
  • 58 Young NP, Daube JR, Sorenson EJ, Milone M. Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2. Muscle Nerve 2010; 41 (6) 758-762
    CrossrefPubMedGoogle Scholar
  • 59 Logigian EL, Ciafaloni E, Quinn LC , et al. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve 2007; 35 (4) 479-485
    CrossrefPubMedGoogle Scholar
  • 60 Suokas KI, Haanpää M, Kautiainen H, Udd B, Hietaharju AJ. Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 2012; 45 (1) 70-74
    CrossrefPubMedGoogle Scholar
  • 61 George A, Schneider-Gold C, Zier S, Reiners K, Sommer C. Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol 2004; 61 (12) 1938-1942
    CrossrefPubMedGoogle Scholar
  • 62 Meola G, Sansone V, Marinou K , et al. Proximal myotonic myopathy: a syndrome with a favourable prognosis?. J Neurol Sci 2002; 193 (2) 89-96
    CrossrefPubMedGoogle Scholar
  • 63 Akiguchi I, Nakano S, Shiino A , et al. Brain proton magnetic resonance spectroscopy and brain atrophy in myotonic dystrophy. Arch Neurol 1999; 56 (3) 325-330
    CrossrefPubMedGoogle Scholar
  • 64 Chang L, Ernst T, Osborn D, Seltzer W, Leonido-Yee M, Poland RE. Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. Arch Neurol 1998; 55 (3) 305-311
    CrossrefPubMedGoogle Scholar
  • 65 Tieleman AA, Knoop H, van de Logt AE, Bleijenberg G, van Engelen BG, Overeem S. Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. J Neurol Neurosurg Psychiatry 2010; 81 (9) 963-967
    CrossrefPubMedGoogle Scholar
  • 66 Schoser BG, Ricker K, Schneider-Gold C , et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 2004; 63 (12) 2402-2404
    CrossrefPubMedGoogle Scholar
  • 67 Heatwole C, Johnson N, Goldberg B, Martens W, Moxley III R. Laboratory abnormalities in patients with myotonic dystrophy type 2. Arch Neurol 2011; 68 (9) 1180-1184
    CrossrefPubMedGoogle Scholar
  • 68 Johnson N, Heatwole CR. Myotonic dystrophies. In: Tawil RN, Venance S, , eds. Neuromuscular Disorders. Oxford, UK: Wiley-Blackwell; 2011: 80-86
    CrossrefGoogle Scholar
  • 69 Vihola A, Bassez G, Meola G , et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 2003; 60 (11) 1854-1857
    CrossrefPubMedGoogle Scholar
  • 70 Schoser BG, Schneider-Gold C, Kress W , et al. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve 2004; 29 (2) 275-281
    CrossrefPubMedGoogle Scholar
  • 71 Pisani V, Panico MB, Terracciano C , et al. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. Muscle Nerve 2008; 38 (5) 1405-1411
    CrossrefPubMedGoogle Scholar
  • 72 Orngreen MC, Olsen DB, Vissing J. Aerobic training in patients with myotonic dystrophy type 1. Ann Neurol 2005; 57 (5) 754-757
    CrossrefPubMedGoogle Scholar
  • 73 Kilmer DD, McCrory MA, Wright NC, Aitkens SG, Bernauer EM. The effect of a high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1994; 75 (5) 560-563
    PubMedGoogle Scholar
  • 74 Logigian EL, Martens WB, Moxley IV RT , et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010; 74 (18) 1441-1448
    CrossrefPubMedGoogle Scholar
  • 75 Desaphy JF, De Luca A, Didonna MP, George Jr AL, Camerino Conte D. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. J Physiol 2004; 554 (Pt 2) 321-334
    CrossrefPubMedGoogle Scholar
  • 76 Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev 2006; (1) CD004762
    PubMedGoogle Scholar
  • 77 Damian MS, Gerlach A, Schmidt F, Lehmann E, Reichmann H. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001; 56 (6) 794-796
    CrossrefPubMedGoogle Scholar
  • 78 MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002; 59 (12) 1876-1880
    CrossrefPubMedGoogle Scholar
  • 79 White RJ, Bass SP. Myotonic dystrophy and paediatric anaesthesia. Paediatr Anaesth 2003; 13 (2) 94-102
    CrossrefPubMedGoogle Scholar
  • 80 Weingarten TN, Hofer RE, Milone M, Sprung J. Anesthesia and myotonic dystrophy type 2: a case series. Can J Anaesth 2010; 57 (3) 248-255
    PubMedGoogle Scholar
  • 81 Rudnik-Schöneborn S, Zerres K. Outcome in pregnancies complicated by myotonic dystrophy: a study of 31 patients and review of the literature. Eur J Obstet Gynecol Reprod Biol 2004; 114 (1) 44-53
    CrossrefPubMedGoogle Scholar
  • 82 Rudnik-Schöneborn S, Schneider-Gold C, Raabe U, Kress W, Zerres K, Schoser BG. Outcome and effect of pregnancy in myotonic dystrophy type 2. Neurology 2006; 66 (4) 579-580
    CrossrefPubMedGoogle Scholar
  • 83 Newman B, Meola G, O'Donovan DG, Schapira AH, Kingston H. Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy. Neuromuscul Disord 1999; 9 (3) 144-149
    CrossrefPubMedGoogle Scholar
  • 84 Gadalla SM, Lund M, Pfeiffer RM , et al. Cancer risk among patients with myotonic muscular dystrophy. JAMA 2011; 306 (22) 2480-2486
    CrossrefPubMedGoogle Scholar
  • 85 Foff EP, Mahadevan MS. Therapeutics development in myotonic dystrophy type 1. Muscle Nerve 2011; 44 (2) 160-169
    CrossrefPubMedGoogle Scholar
  • 86 Mulders SA, van den Broek WJ, Wheeler TM , et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A 2009; 106 (33) 13915-13920
    CrossrefPubMedGoogle Scholar
  • 87 Wheeler TM, Sobczak K, Lueck JD , et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009; 325 (5938) 336-339
    CrossrefPubMedGoogle Scholar
  • 88 Goemans NM, Tulinius M, van den Akker JT , et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364 (16) 1513-1522
    CrossrefPubMedGoogle Scholar
  • 89 Cirak S, Arechavala-Gomeza V, Guglieri M , et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378 (9791) 595-605
    CrossrefPubMedGoogle Scholar
  • 90 Langlois MA, Lee NS, Rossi JJ, Puymirat J. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther 2003; 7 (5 Pt 1) 670-680
    CrossrefPubMedGoogle Scholar
  • 91 Langlois MA, Boniface C, Wang G , et al. Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem 2005; 280 (17) 16949-16954
    CrossrefPubMedGoogle Scholar
  • 92 Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007; 15 (12) 2070-2079
    CrossrefPubMedGoogle Scholar
  • 93 Warf MB, Nakamori M, Matthys CM, Thornton CA, Berglund JA. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A 2009; 106 (44) 18551-18556
    CrossrefPubMedGoogle Scholar
  • 94 Ward AJ, Rimer M, Killian JM, Dowling JJ, Cooper TA. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet 2010; 19 (18) 3614-3622
    CrossrefPubMedGoogle Scholar
  • 95 Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007; 117 (12) 3952-3957
    PubMedGoogle Scholar